The company's total assets1300 million yuan, employees 55 1 person. Affiliated raw material pharmaceutical factory and plastic packaging factory, holding Hubei Dongsheng Pharmaceutical Co., Ltd. and holding shares in Xinjiang New Special Medicine Sinopharm Co., Ltd., the company has leading modern factory facilities, superior production conditions and standard products, and its products are widely used in the medical field because of their antiviral, antibacterial, anti-inflammatory, antiallergic and health care characteristics. The company has always regarded seizing the commanding heights of science and technology as the foundation of developing enterprises. In order to ensure the forward-looking technology, we attach great importance to R&D investment and strengthen technological innovation and new product development. The company has established a research and development center with strong technical force and a postdoctoral research center of Qianjiang Pharmaceutical Co., Ltd., and established a rapid and virtuous cycle scientific and technological innovation system from research and development to production. The company is committed to aiming at the forefront of international medical science and technology, and introduces 3-4 new drugs every year. At present, 23 new drugs have obtained new drug certificates, and many products have been serialized and produced on a large scale. The company has implemented the 4C marketing model of customer first, which has begun to take shape and passed GMP certification as a whole. At present, it mainly produces and operates seven dosage forms 150 varieties, including eye drops, injections, freeze-drying agents, tablets, capsules, granules and chemical raw materials. At the same time, the office responsibility system, regional agency system and drug bidding system have been vigorously promoted, which has achieved good results and the market share of products has been continuously improved.
The company's flagship product "Jing" brand eye drops series products rank first in the domestic industry in terms of production, sales and market share; Acyclovir series products, cromoglycine raw materials and its series products are among the best in the same industry in China. Azithromycin granules, as the latest antibacterial and anti-inflammatory drugs, took the lead in research and development in China and won the gold medal of industrial famous brand in Hubei Province. Jolie Eye Drops, a new product containing a small dose of preservatives at one time, has reached the international advanced level, won the national key new product certificate and the title of consumer satisfaction commodity in Hubei Province, and levofloxacin hydrochloride ophthalmic gel has filled the domestic blank. "Jing" trademark and "Gantai" trademark were rated as famous trademarks in Hubei Province.
In order to improve the company's comprehensive strength, the company's two industrial parks (Shi Yang Biomedical Industrial Park and Wuhan Dunkou R&D Center) have been put into production one after another, and they have joined the pharmaceutical business field, marking the company's entry into the biopharmaceutical field and the implementation of diversified management into a new development stage. The company will continue to carry forward the enterprise spirit of "unity, pragmatism, Excellence and innovation", continue to maintain the unique advantages of eye drops, high technology and listed companies, focus on the development of pharmaceutical preparations, take eye drops as the main feature, expand the production scale of APIs, take the modernization of antiviral drugs, antibacterial drugs, biopharmaceuticals and traditional Chinese medicine as the development direction, adhere to the concept of "becoming bigger, more refined and stronger in professional fields" and devote itself to production and operation.